CIK: 0001704132
Total reported value
$237.1M
Reporting period: 2026-03-31 · Number of holdings: 8
Foresite Capital Management IV, LLC disclosed 8 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $237.1M and a quarterly turnover rate of 25.1%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "F"
Foresite Capital Management IV, LLC's disclosed holdings carry a Herfindahl concentration index of 0.361 — mathematically equivalent to about 3 equally-sized positions, well below its 8 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes vary widely across the portfolio (a coefficient of variation of 1.47), with a handful of outsized bets alongside many smaller positions.
Recent activity leans toward adding more aggressively to already-large existing positions than to newly initiated ones (a 4.0 percentage-point tilt) — a pattern consistent with a momentum-following approach.
Sector classification currently covers about 14% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Trim MAZE
-70.0% -$17.0M
Trim LYEL
0.0% -$8.6M
Add CYTK
+9.8% $4.1M
Add ALEC
0.0% $2.3M
Add XENE
0.0% $2.1M
Trim PHVS
0.0% $2.4M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PHVS | Pharvaris N.V. | Stock-Other | 56.94% | -0.79% | — | |
| 2 | CYTK | Cytokinetics INC | Stock-Healthcare | 13.99% | +1.31% | +9.82% | |
| 3 | EIKN | Eikon Therapeutics INC | Stock-Other | 8.67% | +8.67% | NEW | |
| 4 | LYEL | Lyell Immunopharma INC | Stock-Other | 6.77% | -3.95% | — | |
| 5 | RLAY | Relay Therapeutics INC | Stock-Other | 4.20% | +0.52% | — | |
| 6 | XENE | Xenon Pharmaceuticals INC | Stock-Other | 3.92% | +0.80% | — | |
| 7 | ALEC | Alector INC | Stock-Other | 3.53% | +0.89% | — | |
| 8 | MAZE | Maze Therapeutics INC | Stock-Other | 1.98% | -7.45% | -69.98% |
Performance for Q3 2026
+7.4%
Performance Last 4 Quarters
+76.6%
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 8 | $237.1M | 25 | |
| 2025-12-31 | 7 | $229.7M | 23 | |
| 2025-09-30 | 6 | $182.6M | 80 | |
| 2025-06-30 | 6 | $123.8M | 0 | |
| 2025-03-31 | 5 | $111.1M | 100 | |
| 2024-12-31 | 4 | $108.8M | 0 | |
| 2024-09-30 | 5 | $153.0M | 0 | |
| 2024-06-30 | 4 | $148.8M | 0 | |
| 2024-03-31 | 5 | $197.9M | 0 | |
| 2023-12-31 | 5 | $197.9M | 0 | |
| 2023-09-30 | 7 | $180.0M | 0 | |
| 2023-06-30 | 7 | $203.4M | 0 | |
| 2023-03-31 | 8 | $192.7M | 0 | |
| 2022-12-31 | 8 | $234.1M | 0 | |
| 2022-09-30 | 8 | $311.0M | 0 | |
| 2022-06-30 | 8 | $371.4M | 0 | |
| 2022-03-31 | 9 | $357.4M | 0 | |
| 2021-12-31 | 9 | $486.0M | 0 | |
| 2021-09-30 | 12 | $679.1M | 0 | |
| 2021-06-30 | 13 | $739.8M | 100 | |
| 2021-03-31 | 13 | $834.8M | 49 | |
| 2020-12-31 | 13 | $920.6M | 89 | |
| 2020-09-30 | 15 | $443.5M | 91 | |
| 2020-06-30 | 12 | $205.3M | 100 | |
| 2020-03-31 | 11 | $81.1M | 100 | |
| 2019-12-31 | 14 | $231.8M | 75 | |
| 2019-09-30 | 19 | $309.4M | 38 | |
| 2019-06-30 | 22 | $353.8M | 65 | |
| 2019-03-31 | 16 | $278.3M | 56 | |
| 2018-12-31 | 18 | $217.9M | 57 | |
| 2018-09-30 | 21 | $305.0M | 30 | |
| 2018-06-30 | 17 | $293.4M | 57 | |
| 2018-03-31 | 18 | $241.2M | 56 | |
| 2017-12-31 | 13 | $142.7M | 0 |
Foresite Capital Management IV, LLC's most significant position changes for 2026-03-31: New buy: Eikon Therapeutics INC (EIKN); Trim: Maze Therapeutics INC (MAZE) — shares -69.98%; Add: Cytokinetics INC (CYTK) — shares +9.82%.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CYTK | Cytokinetics INC | +1.3% | +9.82% | Add |
| 2 | ALEC | Alector INC | +0.9% | — | Unchanged |
| 3 | XENE | Xenon Pharmaceuticals INC | +0.8% | — | Unchanged |
| 4 | RLAY | Relay Therapeutics INC | +0.5% | — | Unchanged |
| 5 | PHVS | Pharvaris N.V. | -0.8% | — | Unchanged |
| 6 | LYEL | Lyell Immunopharma INC | -4% | — | Unchanged |
| 7 | MAZE | Maze Therapeutics INC | -7.5% | -69.98% | Trim |
| 8 | EIKN | Eikon Therapeutics INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-12 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-14 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-13 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-13 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-13 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-11 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-12 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-13 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-14 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-12 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-13 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-11 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-11-12 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-08-16 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-05-17 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-02-16 | 13F-HR | View on EDGAR |
| 2020-09-30 | 2020-11-13 | 13F-HR | View on EDGAR |
| 2020-06-30 | 2020-08-13 | 13F-HR | View on EDGAR |
| 2020-03-31 | 2020-05-28 | Amendment | View on EDGAR |
| 2020-03-31 | 2020-05-14 | 13F-HR | View on EDGAR |
| 2019-12-31 | 2020-02-14 | 13F-HR | View on EDGAR |
| 2019-09-30 | 2019-11-13 | 13F-HR | View on EDGAR |
| 2019-06-30 | 2019-08-13 | 13F-HR | View on EDGAR |
| 2019-03-31 | 2019-05-14 | 13F-HR | View on EDGAR |
| 2018-12-31 | 2019-02-13 | 13F-HR | View on EDGAR |
| 2018-09-30 | 2018-11-13 | 13F-HR | View on EDGAR |
| 2018-06-30 | 2018-08-14 | 13F-HR | View on EDGAR |
| 2018-03-31 | 2018-05-15 | 13F-HR | View on EDGAR |
| 2017-12-31 | 2018-02-13 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0000918504
Total reported value
$237.1M
89 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0002040070
Total reported value
$237.1M
62 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0002108771
Total reported value
$237.1M
56 stks
2026-03-31
AUM within 0.0% of this institution
Institutions with overlapping top holdings
CIK 0001776382
Total reported value
$280.6M
6 stks
2026-03-31
2 of the top 5 holdings overlap, including Pharvaris N.V.
CIK 0000310158
Total reported value
$349.4M
14 stks
2026-03-31
1 of the top 5 holdings overlap, including Eikon Therapeutics INC
CIK 0001017645
Total reported value
$2.1B
12 stks
2026-03-31
1 of the top 5 holdings overlap, including Pharvaris N.V.